Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.62 HKD | +0.35% |
|
+3.86% | -58.66% |
Jul. 09 | MicroPort Scientific Forecasts Decline in Net Loss for H1 on Higher Revenue | MT |
Jul. 08 | MicroPort MedBot Raises HK$114 Million from Share Placement | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-58.66% | 1.06B | - | ||
+2.62% | 208B | B | ||
+6.44% | 182B | B- | ||
+29.61% | 155B | B- | ||
+34.96% | 115B | A- | ||
+2.81% | 66.52B | A- | ||
+17.38% | 53.93B | B+ | ||
-4.51% | 46.26B | B+ | ||
-5.77% | 38.22B | A | ||
+3.71% | 36.6B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2252 Stock
- Ratings Shanghai MicroPort MedBot (Group) Co., Ltd.